ASX:CUV Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Clinuvel Pharmaceuticals Stock (ASX:CUV) 30 days 90 days 365 days Advanced Chart Get CUV alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume124,193 shsAverage VolumeN/AMarket CapitalizationA$563.18 millionP/E Ratio15.95Dividend Yield0.44%Price TargetN/AConsensus RatingN/A Company Overview Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia. Read More Receive CUV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CUV Stock News HeadlinesClinuvel Pharmaceuticals Reports Robust FY2025 Performance and Strategic Growth PlansSeptember 5 at 2:12 AM | msn.com3 ASX Growth Stocks With High Insider OwnershipSeptember 3 at 4:45 PM | finance.yahoo.comTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spending that rivals wartime levels. But according to two veteran analysts, this isn’t recklessness. It’s a deliberate mobilization for what could be America’s most consequential arms race yet. The warning signs are everywhere: ballooning deficits, record shortfalls, and strategic moves to secure resources and manufacturing. If you’ve got money in the market or savings in the bank, understanding what’s happening behind the scenes may be critical. | Porter & Company (Ad)Clinuvel Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowAugust 29, 2025 | finance.yahoo.comClinuvel Pharmaceuticals Declares Dividend, Reinforcing Shareholder ValueAugust 28, 2025 | tipranks.comCLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplistAugust 22, 2025 | markets.businessinsider.comCLINUVEL Plans Nasdaq Uplisting to Boost U.S. Market PresenceAugust 22, 2025 | msn.comCUV Share Price History | Clinuvel Pharmaceuticals Limited | AFRAugust 20, 2025 | afr.comSee More Headlines CUV Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Clinuvel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clinuvel Pharmaceuticals investors own include Cochlear (COH), CSL (CSL), ResMed (RMD), ARB (ARB), Accent Group (AX1), Corporate Travel Management (CTD) and Mineral Resources (MIN). Company Calendar Ex-Dividend for 9/18 Dividend9/03/2025Today9/05/2025Record date for 9/18 Dividend9/18/2025Dividend Payable9/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CUV CIKN/A Webwww.clinuvel.com Phone61 3 9660 4900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A$0.70 Trailing P/E Ratio15.95 Forward P/E RatioN/A P/E GrowthN/ANet IncomeA$35.64 million Net Margins40.67% Pretax MarginN/A Return on Equity18.67% Return on Assets14.29% Debt Debt-to-Equity Ratio0.43 Current Ratio8.81 Quick Ratio10.03 Sales & Book Value Annual SalesA$88.18 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow19.36 Book ValueA$4.02 per share Price / BookN/AMiscellaneous Outstanding Shares50,060,000Free FloatN/AMarket CapA$563.18 million OptionableNot Optionable Beta0.92 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (ASX:CUV) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Clinuvel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
